

Cardiovascular disease is the number one cause of death in developed countries.

#### An NIH Bioengineering Research Partnership grant



First, a description of tissue engineering...

Two related ideas:

### tissue engineering - an engineering/biology enterprise

regenerative medicine - mostly biology & and medicine

### **Tissue Engineering**



Start with a **porous matrix** 



Mold to the **shape** of a tissue or organ



Seed with cells (autologous or allogeneic)

Culture the cells and **grow a tissue** or organ

Poly(lactic acid) Poly(glycolic acid) PGLA Collagen

ChondrocytesHepatocytesCardiomyocytesOsteoblasts

Cartilage Liver Heart Bone



Cells seed on poly(lactic acid) fibers

R. Langer, et al.



R. Langer, et al.





From "Engineer's Toolkit" C. Mitcham and R. Duvall



http://www.cen.uiuc.edu/~vincens/peo\_hydrogels.html

#### THE NEW ERA OF REGENERATIVE MEDICINE

Dozens of biotech companies and university labs are developing ways to replace or regenerate failed body parts. Here are a few of the projects:



#### BONE

Bone-growth factors or stem cells are inserted into a porous material cut to a specific shape, creating new laws or limbs. A product that creates shinbones is in clinical trials

**COMPANIES:** Creative Biomolecules, Orguest, Sulzer Orthopedics Biologics, Genetics Institute Osiris Therapeutics, Regeneron,





Organogenesis' Apligral, a human-skin equivalent, is the first engi neered body part to win FDA approval, initially for leg

ulcers. Other skins are in the works for foot ulcers and burns.

**COMPANIES:** Organogenesis, Ad-vanced Tissue Sciences, Integra LifeSciences, LifeCell, Ortec International,



#### PANCREAS

Insulin-manufacturing cells are harvested from pigs, encapsulated in membranes, and injected into the abdomen. The method has been tested in animals and could be in human trials in two years.

COMPANIES: BioHybrid Technologies, Neocrin, Circe Biomedical



#### HEART VALVES, ARTERIES, AND VEINS

A 10-year initiative to build a heart has just started. Genetically engineered pro-teins have been successfully used to regrow blood vessels.

COMPANIES: Organogenesis, Advanced Tissue Sciences, Genetech, LifeCell, Reprogenesis.

DATA: BUSINESS WEEK, DRUG & MARKET DEVELOPMENT REPORTS

#### SALIVA GLANDS



saliva glands damaged by disease or radiation. Glands are also being engineered to secrete healing drugs. The technique has proven successful in mice.

COMPANIES: None yet.



Cartilage cells are taken from the patient, packed

into a tiny matrix, and injected into the weakened ureter, where they bulk up the tissue walls to prevent urinary backup and incontinance. The method is in late-phase. elinical tri-

#### COMPANIES:

Doctors at Children's Hospital in Boston have grown bladders from skin cells and implanted them in sheep.

They are about to try the same process on a patient

on the market that regrows knee cartilage. A chest has been grown for a boy and a human

ear on a mouse.

COMPANIES: Genzyme Tissue. Biomatrix, Integra LifeSciences, Advanced Tissue Sciences, ReGen **Biologics**, Osiris Therapeutics

#### TEETH Enamel matrix



Java

Niking

railers

ersan.

entiting

**COMPANIES:** Biora, Atrix Labo ratories, Creative BioMolecules



ic nipple by inserting a ball of cartilage. Researchers are now trying to grow a whole cosmetic breast.

**COMPANIES:** Reprogenesis, Integra LifeSciences.

#### LIVER



A spongy membrane is built. up and then seeded with liver cells. Organs the size of a dime

have been grown, but a full-size liver could take 10 years due to its complexity.

**COMPANIES:** Advanced Tissue Sciences, Human Organ Sciences, Organogenesis,



ing them at the site of damage to encourage regeneration or seeding them along biodegradable filaments and implanting them. Rats have been made to walk again.

COMPANIES: Acorda, Regeneron, CytoTherapeutics, Guilford Pharmaceuticals.







**COMPANIES:** Reprogenesis.



### **Tissue Engineering sounds great!**

Are there challenges remaining?

The hard problems in tissue engineering:

Angiogenesis (blood vessel formation) Cell Differentiation (on and off) Multiple cell types

Inflammation

Immunology

Mechanics

Sterilization

Packaging

# **Myocardial Tissue**



from: Myocardium, Vessels and Calcium, Lossnitzer, Pfennigsdorf, & Bräuer, 1983.

### **Heart Muscle Tissue Engineering**

Issues that need to be addressed for cardiac muscle tissue engineering :

- 1. slow growing (or non-growing) cardiomyocytes
- 2. tissue engineering scaffolds that are elastomeric,
- 3. aligning/orienting cardiomyocytes
- 4. vascularizing the growing cell mass
- 5. innervating the tissue
- 6. incorporating strong and flexible ECM in the tissue,
- 7. inhibiting the inflammatory response (fibrosis) upon implantation,
- 8. preventing tissue rejection and
- 9. fusing the engineered heart muscle with existing heart tissue.

#### Elements that must coalesce to reach our goal: heart muscle





#### **BEAT** investigators

Ratner / Vogel / Nair porous polymers (hydrogel, PLA), aphrons Sanders fibrous materials / biomechanical considerations Woodhouse (U. Toronto) novel biodegradable polymers Heller (Advanced Polymer Technologies, Inc.) novel biodegradable polymers Hauschka/Angello muscle cells Murry healing in the heart

Stayton / Hoffman cell orientation/fusion / gene delivery Bornstein ECM Allen Endothelium, surgical aspects Vernon/Sage Angiogenesis Mansbridge/Ratcliff (ATS, Inc.) Stem cells / bioreactors & packaging Hauch Microscopy, coordination

#### The strategy to grow heart muscle...





### Let's start with scaffolds...

Pores, textures, roughnesses have a large effect on cells and living organisms!

#### **Criteria and Considerations for Scaffolds for Heart Tissue Engineering**

**Biodegradable Elastomeric Control of pore size & distributions** A high void fraction (mostly air) Oriented pores for muscle **Random networks for angiogenesis** Support cell attachment how to get cells into the scaffold? **Biocompatible / low inflammation** Deliver drugs, cytokines, genes Sectionable / stainable **Sterilizable** Manufacturable



For further information, see:

Brauker, JH; Carr-Brendel, VE; Martinson, LA; Crudele, J; Johnston, WD; Johnson, RC (1995): Neovascularization of synthetic membranes directed by membrane microarchitecture. J. Biomed. Mater. Res. 29, 1517-1524.

### **Approaches to Porous Matrices**

Microsphere template gels Controlled release from templated gels **Electrospun fibrous matrices and materials (Sanders)** Salt leachates **Chitosan matrices (Sandy Chian)** Aphron foams (Prabha Nair with Georgia Tech) Parallel channels in materials Laminin printed lines (McDevitt, Stayton) **Unique polymers** Biodegradable polyurethanes (Kim Woodhouse) Elastins (Kim Woodhouse)

Extracted tissue (Kim Woodhouse)

Poly(ortho esters) (Jorge Heller)

Biodegradable methacrylates (Andrew Marshall)

### Two approaches:

### Alginate-Amino Acid Aphron



# Microsphere templated hydrogel 5 µm pores



Andrew Marshall

### Microsphere template gels



Microspheres in monomer solution



**Preparation** 

Gel (crosslink) the monomer



Extract out the microspheres

### **Darcy's Law**

Henry Philibert Gaspard Darcy, (1803-1858)

### The rate of flow of liquids through porous media

 $Q = kS \ \underline{H+e}$ 

where

- Q = volume of liquid/unit time,
- S = porous bed area,
- e = porous bed thickness,
- H = height of the liquid on the bed
- k = coefficient ( nature of the bed, etc.)



http://biosystems.okstate.edu/darcy/

### How do we measure interconnectivity?

• We can use a correlation to determine the critical throat radius from measurable properties.\*

 $r_{\rm c}$  = critical throat radius (~1.4 µm) k = hydraulic permeability (~1.3 × 10<sup>-11</sup> cm<sup>2</sup>)

= tortuosity (~1.2)

= porosity (%68)

$$r_c = \sqrt{\frac{226k\alpha}{\phi}}$$

1



<sup>\*</sup>Katz, A.J. and Thompson, A.H., *Phys. Rev. B*, **34**, 8179 (1986)

### **Quantitative Characterization of Porous Matrices**

**Porosity (68%)** 

**Pore size (~5 μm diam.)** 

Pore throat size (~1.8 μm diam.)

Throat/Pore ratio (~3.8)

**Tortuosity** (~1.2)

### 3-D crystalline array of fused 60µm PMMA beads



### Crystalline surface of packed 60µm beads



# Porous pHEMA templated with crystalline array of 60µm beads



**Engineering control of the texture and porosity** 

### Another approach to achieve orientation/alignment: Microcontact printing (µCP)



### **Laminin Patterning**

### 5 x 20 μm

#### 10 x 40 µm



Todd McDevitt, P. Stayton

### **Junction Staining**

#### **N-cadherin**

#### **Connexin43**



Neonatal rat cardiomyocytes, 7 days in culture Nuclei - DAPI (blue) Actin - Phalloidin (red)

T. McDevitt, P. Stayton, C. Murry and S. Hauschka

### **Intercalated Disks**

#### **N-cadherin**

#### **Connexin43**



#### Neonatal rat cardiomyocytes, 4 days in culture Nuclei - DAPI (blue) Actin - Phalloidin (red)

T. McDevitt, P. Stayton, C. Murry and S. Hauschka Heart muscle is much more than cardiomyocytes!

Cardiomyocytes

Endothelium

Nerve

ECM

### Angiogenesis (Dr. Robert Vernon, Dr. Helene Sage)





Endothelial sprouts through Nucleopore filter

1 and 2 appear to be growing toward each other -- there are filopodia extending from the tip of each sprout.3 appears to be thin-walled and hollow.

Robert Vernon

Conversion of a Porous Membrane into a Testbed for Capillary Sprouting



Embedment in collagen gel

R. Vernon

#### Traction-Mediated Uniaxial Organization of Cells & ECM in a Collagen Membrane



R. Vernon







### **Electrospinning of fibro-porous materials**

"skinny fibers"



Joan Sanders, et al.

### **Studies with ultrafine fibers**

# Polypropylene fibers



<u>Fiber spacing</u> 80-100 μm 40-60 μm 10-20 μm

**Joan Sanders Lab** 

# Aortic smooth muscle cells seeded on fibronectin-coated polypropylene fibers



 $Bar = 20 \ \mu m$ 

**Joan Sanders Lab** 

# **Micro-fiber arrays**

#### SMCs are seeded onto single, parallel aligned micro-fibers

• 30 min: cells attach to the fibers

• 2 days: cell layers form

• 7 days: layers attach to form bridges between fibers



#### $bar = 50 \ \mu m$

JE Sanders, et al

### **Dependence on micro-fiber spacing**



10-20 µm

40-60 µm

80-100 µm

bar=100 mm

Continuous cell sheets form at 10-20  $\mu$ m (top) and 40-60  $\mu$ m (middle) spacings; large holes form at 80-100  $\mu$ m (bottom)



Fibers remain evenly separated with continuous cell sheets only at the 40-60 μm spacing

JE Sanders, et al



Another idea:

### **Build up tissues from cell layers**



### pNIPAM -- a Thermally Responsive Polymer

#### Room temperature: A soft, swollen hydrogel



Body temperature: A hard plastic



- M. Heskins & J. E. Guillet (1968)
- Allan Hoffman (1990+)

# We coat surfaces with the NIPAM polymer in a glow discharge (ppNIPAM)



### **Smooth muscle cells on ppNIPAM for 3 Hours**

DMEM/1.5% FBS

Room temperature

23°C



37°C



Xuanhong Cheng

### **BASMC Adhesion from Serum Containing DMEM**



I0 times increase in cell adhesion on ppNIPAM at 37°C compared to 23 °C.
Cell adhesion on ppNIPAM is reversible.

Xuanhong Cheng



### **Detachment of Confluent BAEC Cell Sheet**



Xuanhong Cheng

# Criteria for cells for tissue engineering

robustness
reproductive vitality
differentiation potential
phenotypic stability
phenotypic functionality
cell line purity
freedom from viral contamination
immunologic issues.

### **BEAT** Cell Differentiation, Modification and Proliferation Experiments

Stem cells (mouse) differentiate to cardiac cells

Patterned cardiac myocytes to Purkinje fibers

Stimulate cardiomyocyte proliferation

Stimulation of muscle cell graft growth in vivo

Co-culture of skeletal muscle and vascular cells

Enhancing the number of laminin receptors in cells



# **Cell Separation scheme**





# **GFP transfection of cardiomyocytes**



1 week after seeding

Charles Murry, Jeanette Nissbaum

### A Bio-engineered Ventricular Patch Will Require A Purkinje Fiber Conduction System





Working Cardiac Myocyte



Purkinje Fiber Cell

S. Hauschka

# **The BEAT Strategic Plan**

### Why?

- •We have 3.5 years to accomplish a very difficult task
- •10 investigators need coordination to work together
- •We are exploring many avenues -- are all productive forever?
- •A highly goal-oriented program, rather than curiosity driven
- •People are looking to us to succeed
- •Resources are limited -- how to use them best?
- •Flexibility is critical / creative problem solving essential



Anti-life (2000)	<b>Pro-life</b> (2000+)
Heart disease Cancer Diabetes New diseases? Stress Environmental Pollution Wearing out of "parts"	Cancer cure? Organ regeneration? Telomers and aging Alzheimer's cure Diabetes cure

Prolong Life with Good Quality

2005

2003

2001

1999

Prosthetic Parts Pharmaceutics Technology Tissue Engineering?

2007

2009

2011

2013 +++

Acknowledgements:

BEAT investigators, researchers and students

The NIH for funding BEAT

The NSF for nucleating BEAT through UWEB

